COVID-19: communication to Partners, Customers, Suppliers

Fidia has implemented a series of measures, to minimize any potential risks related with the COVID-19 outbreak, guaranteeing full operations in, from and to the factories, as well as transports of goods and supply of materials.

Read More

Fidia Introduces in the US the 3-injection regimen TRILURON™ (sodium hyaluronate)

Florham Park, N.J., December 2, 2019 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid-based products and its wholly owned subsidiary, Fidia Pharma USA Inc., introduce in the US, TRILURON™ (sodium hyaluronate).

Read More

Fidia Pharma USA Inc Announces Expansion into the Dietary Supplement Market with Launch of CartiJoint™ FORTE

CartiJoint™ FORTE is the First Product in Fidia’s New Dietary Supplement Portfolio; Uniquely formulated with bioactive Bio-Curcumin Curcugreen™

Read More

Our Four Leading Principles: